The question is whether adding AOD 9604 justifies the additional cost, injection frequency, and complexity
Regulatory & Legal Status AOD-9604 has no FDA-approved therapeutic use and has never been cleared for human consumption by any government health authority worldwide it exists in a pre-clinical/discontinued-development status, which is the basis for its banned classification
With neurological symptoms: 1000 g intramuscularly on alternate days should be continued for up to three weeks or until there is no further improvement
(4) AOD 9604 Peptide and Cell Regeneration Additional research was conducted to study the regenerative potential of the peptide
H 2 -receptor antagonist examples include cimetidine, famotidine, nizatidine, and ranitidine
AOD-9604 works in the body on adipose tissue, also known as body fat tissue